Jordi is responsible for making and managing investments at Ysios Capital. Prior to joining Ysios in 2019, Jordi worked at Vida Ventures in Boston, where he focused on opportunities in oncology, gene therapy and ophthalmology.
Jordi has more than 10 years’ experience in biomedical research. He completed a PhD at the European Molecular Biology Laboratory (EMBL), where he studied fundamental aspects of non-coding RNA biology. As a post-doctoral fellow at Harvard University, Jordi worked on the development of novel therapeutic strategies for colorectal cancer by studying signalling pathways in cancer stem cells. Jordi has published lead author papers in prestigious journals such as Cell and Cell Stem Cell.
Jordi holds a Bachelor´s degree in Biochemistry from the University of Barcelona, and a PhD in Molecular Biology from the European Molecular Biology Laboratory (EMBL).
Jordi is a Board Member at Northsea Therapeutics, Splice Bio and a Board Observer at Cytoki Pharma, and Adcendo .